HOME >> MEDICINE >> NEWS
AstraZeneca announces SYMBICORT is now available in the US

Wilmington, Del. June 25, 2007 -- AstraZeneca announced today that SYMBICORT (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler (pMDI) is now available in the United States for the long-term maintenance treatment of asthma in patients 12 years of age and older.

Administered twice daily, SYMBICORT is a combination of two proven asthma medications budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA). For many patients, this combination treatment offers improved asthma control as early as day one that is sustained over 12 weeks. SYMBICORT also delivers improved lung function occurring within 15 minutes of beginning treatment. SYMBICORT does not replace fast-acting inhalers for sudden attacks.

SYMBICORT is available in two dose strengths, 80/4.5 and 160/4.5 mcg of budesonide and formoterol, respectively. SYMBICORT is approved for patients whose disease is not adequately controlled on another asthma-controller medication (e.g., low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies.

With the U.S. launch of SYMBICORT, millions of asthma sufferers will have a new choice of fixed combination therapy to help achieve control of their asthma, said Chris OBrien, MD, PhD, senior director, Medical Science, AstraZeneca.

Asthma is one of the most serious chronic diseases in the U.S. It is estimated that more than 20 million Americans suffer from the condition and, if not properly managed, asthma can be life-threatening.

The U.S. availability of SYMBICORT holds great promise for millions of Americans that suffer from asthma, said Tony Zook, president and chief executive officer, AstraZeneca U.S. The addition of SYMBICORT to our respiratory portfolio reinforces AstraZenecas commitment to developing new, effective treatments, and provides patients and physicians
'"/>

Contact: Tracy Knudsen
Tracy.Knudsen@astrazeneca.com
302-885-1933
AstraZeneca
25-Jun-2007


Page: 1 2

Related medicine news :

1. AstraZeneca, University of Miami, and Humana collaborate to improve consumer health
2. AstraZeneca and M. D. Anderson Cancer Center form umbrella scientific collaboration agreements
3. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
4. Weill Cornell Medical College announces gifts totaling $400M
5. GSK announces launch of largest ever Phase III trial in lung cancer treatment
6. Elsevier announces launch of Brain Stimulation
7. NSW Premier announces $15M for childrens cancer research
8. National Inventors Hall of Fame announces 2007 inductees
9. Emory University announces new Global Health Institute
10. BioMed Central announces Journal of Medical Case Reports
11. Tibotec Therapeutics announces start of largest US study on HIV treatment in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... , ... An in-depth computational analysis of genetic variants implicated in both schizophrenia ... that may explain why susceptibility to one of the disorders could place individuals at ... in the journal npj Schizophrenia. , “There is a wealth of genomic data ...
(Date:2/24/2017)... ... ... With millions of Americans and people worldwide struggling with ... aware of our options and are empowered with strength and information throughout the ... newest edition of "Vision and Hearing" in USA Today, that will educate readers ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University Institute for ... engaged in or interested in palliative care education and research. The Symposium, “Innovate. ... North County San Diego on Sept. 28 and 29, 2017, on the campus of ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business ... in radiology marketing programs at the annual Building Better Radiology Marketing Programs ... Worth Hotel in Fort Worth, Texas. Nine awards are given out in five categories. ...
(Date:2/23/2017)... Austin, TX (PRWEB) , ... February 23, 2017 ... ... has announced an official 2017 partnership with The Jensie Gran Fondo of Marin. ... UVA and UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24, 2017 Medivir AB (Nasdaq ... a new Board of Directors that will be submitted ... Committee comprises representatives of the company,s three largest shareholders ... who have accepted a seat on the Nomination Committee, ... the 2016-2017 Nomination Committee was as follows:  ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... drug pricing data and benchmarks in the global Autism Spectrum Disorder ... What are the key drugs marketed for Autism Spectrum ...
(Date:2/23/2017)... Australia , Feb. 23, 2017 ITL Limited, ( ... announce excellent results for the half year ended 31 December 2016 ... BioMedical Growth Update" presentation can be viewed here . ... $2.12m (Dec 2015: $1.04m; up 104%) Earnings per ... Revenue of $17.5m (Dec 2015: $15.7m; up 11%) ...
Breaking Medicine Technology:
Cached News: